{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:22:21Z","timestamp":1792678941411,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Inotropic support is commonly used in patients with cardiogenic shock (CS). High-quality data guiding the use of dobutamine or milrinone among this patient population is limited. We compared the efficacy and safety of these two inotropes among patients with low cardiac output states (LCOS) or CS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched up to February 1, 2023, using key terms and index headings related to LCOS or CS and inotropes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA EXTRACTION:<\/jats:title>\n            <jats:p>Two independent reviewers included studies that compared dobutamine to milrinone on all-cause in-hospital mortality, length of ICU stay, length of hospital stay, and significant arrhythmias in hospitalized patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SYNTHESIS:<\/jats:title>\n            <jats:p>A total of eleven studies with 21,084 patients were included in the meta-analysis. Only two randomized controlled trials were identified. The primary outcome, all-cause mortality, favored milrinone in observational studies only (odds ratio [OR] 1.19 (95% CI, 1.02\u20131.39; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.02). In-hospital length of stay (LOS) was reduced with dobutamine in observational studies only (mean difference \u20131.85 d; 95% CI \u20133.62 to \u20130.09; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.04). There was no difference in the prevalence of significant arrhythmias or in ICU LOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Only limited data exists supporting the use of one inotropic agent over another exists. Dobutamine may be associated with a shorter hospital LOS; however, there is also a potential for increased all-cause mortality. Larger randomized studies sufficiently powered to detect a difference in these outcomes are required to confirm these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000962","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T16:00:09Z","timestamp":1693238409000},"page":"e0962","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Milrinone and Dobutamine in Cardiogenic Shock: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"5","author":[{"given":"Omar","family":"Abdel-Razek","sequence":"first","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Jung","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada."},{"name":"Division of Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Parlow","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Motazedian","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Prosperi-Porta","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Visintini","sequence":"additional","affiliation":[{"name":"Berkman Library, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Marbach","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Knight Cardiovascular Center, Oregon Health and Science University, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Daniel","family":"Ramirez","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Simard","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada."},{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Labinaz","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mathew","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[{"name":"CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada."},{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","article-title":"Management of cardiogenic shock complicating myocardial infarction: An update 2019.","volume":"40","author":"Thiele","year":"2019","journal-title":"Eur Heart J"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MCC.0000000000000845","article-title":"Epidemiology and causes of cardiogenic shock.","volume":"27","author":"Berg","year":"2021","journal-title":"Curr Opin Crit Care"},{"key":"R4-20240807","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005618","article-title":"Epidemiology of shock in contemporary cardiac intensive care units.","volume":"12","author":"Berg","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00392-017-1182-2","article-title":"Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States.","volume":"107","author":"Shah","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock.","volume":"341","author":"Hochman","year":"1999","journal-title":"N Engl J Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"469.e1","DOI":"10.1016\/j.ahj.2006.05.031","article-title":"A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.","volume":"152","author":"Burkhoff","year":"2006","journal-title":"Am Heart J"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2016.10.022","article-title":"Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction.","volume":"69","author":"Ouweneel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCULATIONAHA.118.038201","article-title":"Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: Long-term 6-year outcome of the Randomized IABP-SHOCK II Trial.","volume":"139","author":"Thiele","year":"2018","journal-title":"Circulation"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.118.036614","article-title":"Impella Support for acute myocardial infarction complicated by cardiogenic shock.","volume":"139","author":"Schrage","year":"2019","journal-title":"Circulation"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock.","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.25011\/cim.v42i2.32813","article-title":"Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis.","volume":"42","author":"Mathew","year":"2019","journal-title":"Clin Invest Med"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias).","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mhj.2003.50","article-title":"Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: A prospective, randomized trial.","volume":"145","author":"Aranda","year":"2003","journal-title":"Am Heart J"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1592\/phco.26.8.1078","article-title":"Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.","volume":"26","author":"Arnold","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"696138","DOI":"10.3389\/fcvm.2021.696138","article-title":"Inotrope use and intensive care unit mortality in patients with cardiogenic shock: An analysis of a large electronic intensive care unit database.","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.ahj.2008.01.015","article-title":"Resource utilization in patients hospitalized with heart failure: Insights from a contemporary national hospital database.","volume":"155","author":"Hauptman","year":"2008","journal-title":"Am Heart J"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1074248418797357","article-title":"Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock.","volume":"24","author":"Lewis","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"11795468211049449","DOI":"10.1177\/11795468211049449","article-title":"Predictors of in-hospital mortality in cardiogenic shock patients on vasoactive or inotropic support.","volume":"15","author":"Nandkeolyar","year":"2021","journal-title":"Clin Med Insights Cardiol"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1527-5299.2005.04359.x","article-title":"Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure.","volume":"11","author":"Scroggins","year":"2005","journal-title":"Congest Heart Fail"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1067\/mhj.2001.119610","article-title":"Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.","volume":"142","author":"Yamani","year":"2001","journal-title":"Am Heart J"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1939","article-title":"Effect of inpatient dobutamine versus milrinone on out-of-hospital mortality in patients with acute decompensated heart failure.","volume":"37","author":"King","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.cardfail.2010.06.252","article-title":"Dobutamine versus milrinone in left ventricular failure.","volume":"16","author":"Mazurek","year":"2010","journal-title":"J Card Fail"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/ehjacc\/zuab052","article-title":"The association between mean arterial pressure and outcomes in patients with cardiogenic shock: Insights from the DOREMI trial.","volume":"10","author":"Parlow","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-021-03706-2","article-title":"Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: A subgroup analysis of the DOREMI trial.","volume":"25","author":"Di Santo","year":"2021","journal-title":"Crit Care"},{"key":"R34-20240807","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.cardfail.2021.08.012","article-title":"Lactate clearance is associated with improved survival in cardiogenic shock: A Systematic Review and Meta-Analysis of Prognostic Factor Studies.","volume":"27","author":"Marbach","year":"2021","journal-title":"J Card Fail"},{"key":"R35-20240807","doi-asserted-by":"crossref","first-page":"e021570","DOI":"10.1161\/JAHA.121.021570","article-title":"Implications of myocardial infarction on management and outcome in cardiogenic shock.","volume":"10","author":"Jung","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R36-20240807","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jjcc.2022.06.001","article-title":"No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.","volume":"80","author":"Prosperi-Porta","year":"2022","journal-title":"J Cardiol"},{"key":"R37-20240807","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2019.11.023","article-title":"Safety of outpatient milrinone infusion in end-stage heart failure: ICD-level data on atrial fibrillation and ventricular tachyarrhythmias.","volume":"133","author":"Harhash","year":"2020","journal-title":"Am J Med"},{"key":"R38-20240807","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/CIRCHEARTFAILURE.108.839076","article-title":"Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.","volume":"2","author":"Gorodeski","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R39-20240807","first-page":"CD009669","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.","volume":"1","author":"Schumann","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R40-20240807","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock.","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:03:11Z","timestamp":1722992591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000962","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}